Search research articles
Contact Us
Filters
Showing results (81-90 of 96) with videos related to
Page
of 10
Sort By:
Gynecologic Oncology
|
July 28, 2022
Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study
Florence Joly, Michel Fabbro, Dominique Berton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 2015
PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients
Anne de la Rochefordiere, Maud Kamal, Anne Floquet, et al.
Cancer Research Communications
|
June 28, 2023
Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Anne-Sophie Sertier, Anthony Ferrari, Roxane M Pommier, et al.
Gynecologic Oncology
|
January 27, 2023
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial
Gwénaël Ferron, Gaëtan De Rauglaudre, Stéphanie Becourt, et al.
The Lancet. Oncology
|
December 3, 2016
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M Swisher, Kevin K Lin, Amit M Oza, et al.
Bulletin Du Cancer
|
February 6, 2018
[Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer]
Christine Rousset-Jablonski, Fréderic Selle, Elodie Adda-Herzog, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 7, 2019
Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers
Christine Rousset-Jablonski, Fréderic Selle, Elodie Adda-Herzog, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 2014
Incorporation of pazopanib in maintenance therapy of ovarian cancer
Andreas du Bois, Anne Floquet, Jae-Weon Kim, et al.
Lancet (London, England)
|
September 17, 2017
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L Coleman, Amit M Oza, Domenica Lorusso, et al.
Cancer Discovery
|
June 8, 2017
Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Olga Kondrashova, Minh Nguyen, Kristy Shield-Artin, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 96) with videos related to
Sort By:
Page
of 10
Gynecologic Oncology
|
July 28, 2022
Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study
Florence Joly, Michel Fabbro, Dominique Berton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 2015
PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients
Anne de la Rochefordiere, Maud Kamal, Anne Floquet, et al.
Cancer Research Communications
|
June 28, 2023
Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Anne-Sophie Sertier, Anthony Ferrari, Roxane M Pommier, et al.
Gynecologic Oncology
|
January 27, 2023
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial
Gwénaël Ferron, Gaëtan De Rauglaudre, Stéphanie Becourt, et al.
The Lancet. Oncology
|
December 3, 2016
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M Swisher, Kevin K Lin, Amit M Oza, et al.
Bulletin Du Cancer
|
February 6, 2018
[Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer]
Christine Rousset-Jablonski, Fréderic Selle, Elodie Adda-Herzog, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 7, 2019
Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers
Christine Rousset-Jablonski, Fréderic Selle, Elodie Adda-Herzog, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 2014
Incorporation of pazopanib in maintenance therapy of ovarian cancer
Andreas du Bois, Anne Floquet, Jae-Weon Kim, et al.
Lancet (London, England)
|
September 17, 2017
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L Coleman, Amit M Oza, Domenica Lorusso, et al.
Cancer Discovery
|
June 8, 2017
Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Olga Kondrashova, Minh Nguyen, Kristy Shield-Artin, et al.
Page
of 10